Primary vs. Secondary Packaging for Life Sciences: What Compliance Actually Requires

If you are sourcing packaging for a Life Sciences product, the difference between primary and secondary packaging is not a structural question. It is a regulatory one. Getting it wrong does not mean a redesign. It means a warning letter, a product hold, or a pulled retail authorization. Most resources on this topic treat it as a definitions exercise. Primary is the inner layer, secondary is the outer layer, end of story. That framing misses the part that actually matters: FDA and other regulatory bodies apply entirely different requirements to each layer, and misassigning a requirement to the wrong layer is one of the most expensive mistakes a brand can make in packaging development. This post covers what compliance actually requires at each layer, where the common failures happen, and what to verify before you brief a manufacturer or sign off on a production run.

Primary and Secondary Packaging: The Actual Definitions

Primary packaging is the material in direct contact with the product. For a pharmaceutical tablet, that is the blister pack or the bottle. For a liquid supplement, it is the container. For a topical medical device, it is the tube or applicator. Secondary packaging is everything outside that layer. The carton holding the bottle. The box the blister pack slides into. The outer layer carrying the retail-facing label, barcodes, and consumer-facing claims. Tertiary packaging, the shipping case and pallet wrap, is the outermost layer. It has its own requirements but operates under a different regulatory framework than primary and secondary, so it is outside the scope of this post. Where brands run into trouble is in assuming that because primary and secondary are physically connected, the compliance requirements are interchangeable. They are not. FDA treats them separately, and so should your spec documentation.

What FDA Actually Requires at the Primary Layer

Primary packaging requirements for pharmaceutical and regulated supplement products are among the most stringent in any category. Four areas are worth understanding before you get into manufacturer conversations.

Material compatibility

The packaging material must be validated as non-reactive with the product. For liquids and semi-solids, this means extractables and leachables testing, which validates that nothing from the container migrates into the product. This is not optional. It is a pre-market requirement for FDA-regulated categories, and manufacturers who primarily run conventional food or beverage packaging often do not have this process in place.

Child-resistant closure compliance

Under the Poison Prevention Packaging Act, most oral pharmaceutical products and many supplements require child-resistant packaging. The key word is require. The exemption is not assumed. It has to be established and documented. Manufacturers without regulated category experience regularly skip this step because it does not come up in food or beverage work.

Tamper-evident features

OTC drug products require tamper-evident packaging under 21 CFR Part 211. The regulation does not mandate a specific mechanism. A shrink band, breakaway cap, and inner seal all satisfy the requirement. What is not optional is having one. Brands new to the OTC category sometimes treat tamper evidence as a secondary pack decision. It belongs on the primary pack.

Unit-level labeling

For dispensed or unit-dose products, labeling must appear on the immediate container, not only on outer packaging. Brands using minimally printed bottles or blister foil without proper lot and expiry coding consistently run into compliance failures here. If the primary container cannot be identified independently of its outer packaging, it does not meet FDA requirements.

What FDA Actually Requires at the Secondary Layer

The secondary pack carries the full consumer-facing and regulatory label. For Life Sciences products, that means several things that go beyond what most conventional CPG brands are used to managing.

Complete label compliance

The Drug Facts panel for OTC products, the Supplement Facts panel for dietary supplements, net quantity of contents, manufacturer name and address, lot number, expiration date, and all required warning statements all live on the secondary pack. Brands coming from conventional CPG often have strong label design instincts but incomplete regulatory label knowledge. Reviewing the label against current FDA guidance before going to print is not optional in this category.

NDC number placement

For pharmaceutical products with a National Drug Code, the NDC must appear on both the immediate container and the outer packaging. Missing it on either layer is a labeling defect. It sounds simple. It gets missed more often than it should, usually because the inner and outer packaging are being managed by different vendors without a single compliance review across both.

Serialization under DSCSA

Under the Drug Supply Chain Security Act, prescription drug products require a serialized product identifier, a 2D barcode, on the smallest saleable unit. For products moving through wholesale and retail channels, this is non-negotiable. The serialization infrastructure, including the barcode generation, aggregation system, and trading partner data exchange, has to be built before first ship. Brands that discover this requirement at the distributor step are already too late.

Retail channel requirements

Major retail buyers in Life Sciences and supplements layer their own compliance requirements on top of FDA minimums. Club channel, natural grocery, and pharmacy all have specific barcode formats, label size thresholds, and carton construction standards. A package that clears FDA review can still fail a retail compliance audit. Confirming channel-specific requirements before finalizing the secondary pack spec is worth the time.

Where the Failures Actually Happen

Compliance failures in Life Sciences packaging almost always trace back to the same set of mistakes. After 25 years sourcing and vetting packaging in this category, here is where the problems cluster.

Briefing both layers on a single spec sheet

When a brand hands a manufacturer one spec document covering primary and secondary together, the manufacturer defaults to their area of strength. A manufacturer whose core business is secondary packaging will apply secondary-layer thinking to requirements that belong on the primary pack. By the time the misalignment surfaces, tooling is committed and timelines are compressed. Brief each layer separately with its own compliance documentation.

Taking the co-packer’s word on category experience

A co-packer with strong CPG food experience is not automatically qualified to run a regulated supplement or OTC drug product. The question to ask is specific: have you run this regulatory category before, and can you show documentation. “We have run supplements” is a very different answer from “we have documented SOPs for 21 CFR Part 111 compliance and we have passed an FDA facility inspection.” Push for the specific answer. The general one tells you nothing useful.

Under-specifying the primary pack

Brands with conventional CPG backgrounds know how to build a retail-facing box. They tend to spend more time on secondary pack design than on primary pack specification, because the secondary is what consumers and buyers see. FDA does not evaluate on aesthetics. The primary pack is where contamination, leachability, and closure failures happen. It is also where the most serious enforcement risk lives. Invest in the spec accordingly. A well-designed outer carton does not offset a primary packaging compliance failure. The FDA will not be impressed by the shelf presence.

Missing DSCSA serialization for wholesale

Brands launching into wholesale or pharmacy channels regularly discover the DSCSA serialization requirement when a distributor rejects their first shipment. The serialization infrastructure cannot be built retroactively without stopping production. If wholesale or pharmacy is in the distribution plan, DSCSA compliance needs to be in the pre-production plan.

Pre-Production Compliance Checklist by Layer

Before finalizing any Life Sciences packaging spec, run through both layers against this list.

Primary Pack

Material compatibility testing completed or in process
Child-resistant closure requirement confirmed, or exemption documented
Tamper-evident feature specified for OTC drug products
Unit-level labeling confirmed: lot, expiry, NDC if applicable
Extractables and leachables requirement assessed for liquid and semi-solid products
Closure torque and seal integrity spec documented

Secondary Pack

Full regulatory label panel complete: Drug Facts or Supplement Facts as applicable
NDC number present for pharmaceutical products
DSCSA serialization barcode specified for prescription and wholesale channel products
Required warning statements reviewed against current FDA guidance
Retailer-specific compliance requirements confirmed for each channel
Net quantity of contents, manufacturer information, lot and expiry placement confirmed

Questions to Ask Any Life Sciences Packaging Manufacturer

A spec is only as good as the manufacturer’s ability to execute it under compliance conditions. For Life Sciences packaging, that means documented quality systems, not just the right equipment. Ask these questions before committing to a production run.

Are you FDA-registered, and for which product categories?
What quality system do you operate under: cGMP, ISO 15378, or equivalent?
Have you received any FDA warning letters or 483 observations in the past three years?
Who manages your change control process, and how are packaging changes documented?
What is your process if a lot hold or compliance deviation occurs mid-run?

Manufacturers with real compliance infrastructure answer these questions with specifics. Manufacturers who answer vaguely or redirect to their marketing materials are the ones who learn on your run. In a regulated category, that is an expensive lesson.

If You Are Sourcing Life Sciences Packaging Right Now

The compliance failures that delay launches and draw FDA attention almost always start the same way: a misaligned assumption somewhere between the spec and the production floor. Sometimes it is a manufacturer who overstated their regulatory experience. Sometimes it is a brand that did not ask the right questions before tooling was committed. Usually it is both. I have spent 25 years sourcing and vetting packaging across pharmaceutical, nutraceutical, supplement, and regulated CPG categories. I know which manufacturers have genuine compliance infrastructure and which ones are still building it. If you are working through a Life Sciences packaging spec and want a second set of eyes on it, or if you need a qualified manufacturer and want to skip the qualification process, reach out through accesscreativegroup.com or find me on LinkedIn. One conversation is usually enough to tell you where the gap is.

─────────────────────────────────────────────────

Frequently Asked Questions

What is the difference between primary and secondary packaging in Life Sciences?

Primary packaging is in direct contact with the product. Secondary packaging is the outer layer that holds, protects, and labels the primary pack at the consumer and retail level. In Life Sciences, each layer carries distinct regulatory requirements. FDA treats them separately, and compliance failures often result from treating them as a single system. Confusing or combining the requirements in one spec document is one of the most common causes of packaging compliance failures during product development.

What does FDA require on primary packaging for pharmaceutical or supplement products?

For pharmaceutical products, primary packaging materials must be validated for compatibility with the product. Tamper-evident features are required for OTC products under 21 CFR Part 211. Child-resistant closures must comply with PPPA requirements unless a documented exemption applies. Unit-level labeling, including lot number, expiration date, and NDC if applicable, must appear on the immediate container. For liquid and semi-solid products, extractables and leachables testing is a pre-market requirement, not an optional step.

Is serialization required for Life Sciences packaging?

For prescription drug products, the Drug Supply Chain Security Act requires a serialized product identifier, a 2D barcode, on the smallest saleable unit. This applies to products distributed through wholesale and pharmacy channels. The serialization infrastructure must be operational before first shipment. Brands that enter wholesale distribution without DSCSA compliance in place will have shipments rejected at the distributor level.

How do I know if my co-packer is qualified to run Life Sciences packaging?

Ask for their FDA registration status and the specific categories they are registered to manufacture. Ask for quality system documentation and their FDA inspection history, including any warning letters or 483 observations in the past three years. A qualified Life Sciences co-packer can answer these questions directly. Vague or redirected answers are a meaningful signal. The compliance risk of an underqualified manufacturer in a regulated category is not recoverable after production starts.

What are the most common Life Sciences packaging compliance failures?

The failures that show up most consistently are: requirements misassigned between primary and secondary layers, primary pack material compatibility that was never properly validated, DSCSA serialization missing for wholesale channel, co-packer gaps in 21 CFR Part 111 or 211 compliance, and retail channel requirements that go beyond FDA minimums. Nearly all of these are preventable with proper pre-production vetting. They become expensive when they surface at a retail compliance audit or after production has run.

What is a Life Sciences packaging consultant and when do I need one?

A Life Sciences packaging consultant sources, vets, and coordinates packaging manufacturers qualified to operate in regulated categories, including pharmaceutical, nutraceutical, supplement, and medical device. You need one when entering a regulated category for the first time, when scaling production requires qualifying additional manufacturers, or when a current packaging partner is creating compliance exposure. The practical value is access to pre-vetted manufacturers and the ability to compress a qualification process that would otherwise take weeks into a matter of days.